Steady-State Plasma Concentration Profile of Transdermal Rotigotine: An Integrated Analysis of Three, Open-Label, Randomized, Phase I Multiple Dose Studies**Results of study SP630 were partially presented at the 58th Annual Meeting of the American Academy of Neurology, San Diego, California, April 1-8, 2006, and at the 9th Cong

Clinical Therapeutics

Volumn 34, Issue 4, 2012, Pages 966-978

  Elshoff, Jan Peer ^a   Braun, Marina ^a   Andreas, Jens Otto ^a   Middle, Michelle ^b   Cawello, Willi ^a  

^a UCB PHARMA   (Belgium)

^b QdotPharma Early Phase Clinical Unit   (South Africa)

Author keywords

Application site; Bioavailability; Continuous 24 hour drug delivery; Dose proportionality; Rotigotine transdermal patch; Steady state pharmacokinetic profile

Indexed keywords

ROTIGOTINE;

APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BIOEQUIVALENCE; CONSTIPATION; CONTACT DERMATITIS; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG RELEASE; DRUG TOLERABILITY; HEADACHE; HUMAN; INSOMNIA; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PARKINSON DISEASE; RHINOPHARYNGITIS; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADMINISTRATION, CUTANEOUS; BIOLOGICAL AVAILABILITY; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 84859611783     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.02.008     Document Type: Article

References (25)

1. Ahlskog J.E., Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001, 16:448-458.
2. Olanow C.W., Schapira A.H., Rascol O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosc 2000, 23(Suppl):S117-S126.
3. Neupro® transdermal patch. Package Label Accessed February 28, 2012. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000626/WC500026397.pdf.
4. Cawello W., Braun M., Boekens H. Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. Drug Metabol Dispos 2009, 37:2055-2060.
5. Watts R.L., Jankovic J., Waters C., et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007, 68:272-276.
6. Poewe W.H., Rascol O., Quinn N., et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007, 6:513-520.
7. Oertel W.H., Beneš H., García-Borreguero D., et al. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med 2008, 9:228-239.
8. Trenkwalder C., Beneš H., Poewe W., et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2008, 7:595-604.
9. Braun M., Cawello W., Boekens H., Horstmann R. Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine. Br Jl Clin Pharmacol 2009, 67:209-215.
10. Cawello W., Elshoff J.P., Boekens H., et al. Characteristics of rotigotine elimination after patch removal. Euro J Neurol 2006, 13(Suppl 2):85. (abstract no.P1164).
11. 14C] rotigotine by a patch formulation: a mass balance trial. Clin Pharmacokin 2007, 46:851-857.
12. Kehr J., Hu X.J., Goiny M., Scheller D. Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation. J Neural Transm 2007, 114:1027-1031.
13. Stockwell K.A., Scheller D., Rose S., et al. Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction. Expl Neurol 2009, 219:533-542.
14. Schmidt W.J., Lebsanft H., Heindl M., et al. Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements. J Neural Transm 2008, 115:1385-1392.
15. Goetz C.G., Poewe W., Rascol O., et al. Movement Disorder Society task force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004, 19:1020-1028.
16. Declaration of Helsinki - Ethical Principles For Medical Research Involving Human Subjects World Medical Association, Accessed July 28, 2011. http://www.wma.net/en/30publications/10policies/b3.
17. Cawello W. Parameters for Compartment-Free Pharmacokinetics 2001, Shaker-Verlag, Aachen, Germany.
18. Skin Irritation and Sensitization Testing of Generic Transdermal Drug Products 1999, Food and Drug Administration, Guidance for Industry, US Department of Health and Human Services, Center for Drug Evaluation and Research, Washington, DC.
19. Note for Guidance on the Investigation of Bioavailability and Bioequivalence (CPMP/EWP/QWP/1401/98, rev. 1) 2001, European Medicines Agency, The European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP), London, UK.
20. Statistical approaches to establishing bioequivalence Food and Drug Administration, Guidance for Industry, Accessed February 28, 2012. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070244.pdf.
21. Malik M., Andreas J.-O., Hnatkova K., et al. Thorough QT/QTc study in patients with advanced Parkinson's disease: cardiac safety of rotigotine. Clin Pharmacol Therap 2008, 84:595-603.
22. Barry B. Properties that influence percutaneous absorption. Dermatological Formulations; Percutaneous Absorption 1983, 127-233. Marcel Dekker Inc., New York. J. Swarbrick (Ed.).
23. Giladi N., Boroojerdi B., Korczyn A.D., et al. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007, 22:2398-2404.
24. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003, 60:1721-1728. The Parkinson Study Group.
25. Schnitzler A., Leffers K.-W., Häck H.-J. High compliance with rotigotine transdermal patch in the treatment of idiopathic Parkinson's disease. Parkinson Related Disord 2010, 16:513-516.